Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Oryzon Genomics S.A.
DescriptionGenetic test that verifies the presence of the BRAF-V600E mutation in MSI-High tumors in colorectal cancer
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect with high certainty that colorectal tumor is sporadic
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today